Skip to main content
Home > The Daily Extra > Financial News

Chronological Index of BioCentury Extra, The Daily News: Financial News

BioCentury Extra, The Daily News Current Issue
  • FINANCIAL NEWS: Optimer falls on 1Q13 financial results

    Optimer Pharmaceuticals Inc. (NASDAQ:OPTR) fell $2.11 (14%) to $12.81 on Friday after reporting 1Q13 financial results late Thursday that missed the Street. The company reported a 1Q13 loss per share of $0.65, wider …

    Published on 5/10/2013
  • FINANCIAL NEWS: Sequenom jumps on 1Q13 revenues

    Sequenom Inc. (NASDAQ:SGNM) gained $0.47 (13%) to $4.04 on Friday after the company reported 1Q13 revenues of $38.5 million, up 158% over $14.9 million in 1Q12. The Street was expecting $38.3 million. Diagnostics …

    Published on 5/10/2013
  • FINANCIAL NEWS: Warburg Pincus raises $11.2B for eleventh fund

    Warburg Pincus raised $11.2 billion for its eleventh fund, Warburg Pincus Private Equity XI. Warburg invests in healthcare, energy, financial services, technology, media and telecommunications and consumer, industrial …

    Published on 5/10/2013
  • FINANCIAL NEWS: AnGes looks to raise at least $51.2M

    Japanese gene therapy company AnGes MG Inc. (Tokyo:4563) said it hopes to raise at least Y5.1 billion ($51.2 million) through May 19, 2014, through the exercise of 20,000 stock acquisition rights by Merrill Lynch Japan …

    Published on 5/9/2013
  • FINANCIAL NEWS: Dendreon slides on Provenge sales miss

    Shares of Dendreon Corp. (NASDAQ:DNDN) slid $0.71 (15%) to $4.03 on Thursday after the company reported 1Q13 net revenues of prostate cancer drug Provenge sipuleucel-T -- the company's sole marketed product -- that …

    Published on 5/9/2013
  • FINANCIAL NEWS: Frazier raises $282M of $300M for seventh fund

    Frazier Healthcare raised $281.8 million of a planned $300 million for its seventh fund, Frazier Healthcare VII, according to an SEC filing. Frazier's prior fund closed at $600 million in 2007. The firm is primarily …

    Published on 5/9/2013
  • FINANCIAL NEWS: Isis raises $171 million in follow-on

    Antisense technology company Isis Pharmaceuticals Inc. (NASDAQ:ISIS) raised $171 million through the sale of 9 million shares at $19 million in a follow-on underwritten by Goldman Sachs; JPMorgan; Stifel Nicolaus Weisel…

    Published on 5/9/2013
  • FINANCIAL NEWS: NPS reports first Gattex sales

    NPS Pharmaceuticals Inc. (NASDAQ:NPSP) reported 1Q13 earnings on Thursday, including $654,000 in the first sales of Gattex teduglutide, which the company launched in the U.S. in February to treat short bowel syndrome (…

    Published on 5/9/2013
  • FINANCIAL NEWS: Omeros planning $16.2 million offering

    Omeros Corp. (NASDAQ:OMER) proposed late Thursday to raise $16.2 million through the sale of 3.9 million shares at $4.14 in a registered direct offering to RA Capital Management and undisclosed investors. The price is a…

    Published on 5/9/2013
  • FINANCIAL NEWS: Receptos raises $72.8 million in IPO

    Receptos Inc. (NASDAQ:RCPT) raised $72.8 million through the sale of 5.2 million shares at $14 in an IPO late Wednesday. Credit Suisse; Leerink; BMO Capital Markets; and Wedbush are underwriters. The price -- at the low…

    Published on 5/9/2013
  • FINANCIAL NEWS: Jazz reports 1Q13 results, slides on Xyrem generic competition concerns

    Jazz Pharmaceuticals plc (NASDAQ:JAZZ) disclosed in a 10-Q late Tuesday that a modified REMS for narcolepsy drug Xyrem sodium oxybate could include new requirements that could "make it easier for future generic …

    Published on 5/8/2013
  • FINANCIAL NEWS: Lumena raises $23 million in series A

    Lumena Pharmaceuticals Inc. (San Diego, Calif.) debuted on Wednesday with $23 million in a series A round led by Alta Partners, with participation from Pappas Ventures and RiverVest Venture Partners. Pappas' David …

    Published on 5/8/2013
  • FINANCIAL NEWS: PeptiDream planning Japanese IPO

    PeptiDream Inc. (Tokyo, Japan) said it plans to sell 1.7 million shares at Y1,720-Y1,920 in an IPO on the Tokyo Stock Exchange's market of the high-growth and emerging stocks (Mothers). At the Y1,820 mid-point, …

    Published on 5/8/2013
  • FINANCIAL NEWS: Quintiles raises $525 million in IPO

    Quintiles Transnational Corp. (NYSE:Q) raised $525 million through the sale of 13.1 million shares at $40 in an IPO on Wednesday. The price -- at the high-end of Quintiles' proposed $36-$40 range -- values the CRO at $5…

    Published on 5/8/2013
  • FINANCIAL NEWS: Vivus reports more Qsymia sales, in discussions with pharma

    Vivus Inc. (NASDAQ:VVUS) was up $1.17 (10%) to $13.21 on Wednesday after CEO Leland Wilson disclosed on a conference call to discuss the company's 1Q13 earnings that Vivus began discussions with large pharmas to "…

    Published on 5/8/2013
  • FINANCIAL NEWS: Ariad reports first Iclusig sales

    Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) reported $6.4 million in net sales of leukemia drug Iclusig ponatinib -- Ariad's sole marketed product -- in its first full quarter of availability. The Street was expecting $5 …

    Published on 5/7/2013
  • FINANCIAL NEWS: Erytech flat on trading debut

    Erytech Pharma S.A. (Euronext:ERYP) closed off EUR 0.12 to EUR 11.48 in its first day of trading on NYSE Euronext Paris on Tuesday. Last Friday, the company raised EUR 16.7 million ($21.8 million) through the sale of 1.…

    Published on 5/7/2013
  • FINANCIAL NEWS: Portola sets IPO range

    Portola Pharmaceuticals Inc. (South San Francisco, Calif.) amended its IPO and now plans to sell 6.9 million shares at $13-$16. At the $14.50 mid-point, Portola would raise $100.1 million and be valued at $469.2 million…

    Published on 5/7/2013
  • FINANCIAL NEWS: Heat Biologics files for IPO

    Cancer company Heat Biologics Inc. (Miami Beach, Fla.) filed to raise up to $20 million in an IPO underwritten by Aegis Capital. This year, Heat Biologics plans to start Phase II testing of its lead candidate, HS-110, …

    Published on 5/6/2013
  • FINANCIAL NEWS: Santarus' 1Q13 earnings beat Street

    Santarus Inc. (NASDAQ:SNTS) jumped $2.13 (11%) to $21 in early after-hours trading after announcing 1Q13 earnings late Monday that beat the Street. Total revenues for the quarter were $79.4 million, including $41.5 …

    Published on 5/6/2013
  • FINANCIAL NEWS: Stat-Diagnostica raises $22.1 million in series B

    Stat-Diagnostica and Innovation (Barcelona, Spain) raised $22.1 million in a series B round led by new investor Kurma Life Sciences Partners. New investors Idinvest Partners; Boehringer Ingelheim Venture Fund; and Caixa…

    Published on 5/6/2013
  • FINANCIAL NEWS: Alcobra bumps shares for NASDAQ IPO

    Alcobra Ltd. (Tel Aviv, Israel) amended its IPO and now plans to sell 2.3 million shares at $10-$12. An $11 price would raise $25 million and value the company at $112.8 million. Last month, the company said it planned …

    Published on 5/3/2013
  • FINANCIAL NEWS: Erytech raises EUR 16.7 million in French IPO on NASDAQ

    Erytech Pharma S.A. (Lyon, France) raised EUR 16.7 million ($21.8 million) through the sale of 1.4 million shares at EUR 11.60 in an IPO on NYSE Euronext Paris. The EUR 11.60 price values the company at EUR 64.3 million…

    Published on 5/3/2013
  • FINANCIAL NEWS: Gilead shares hit high

    Gilead Sciences Inc. (NASDAQ:GILD) gained $2.97 to $55.15 and hit its all-time split-adjusted high closing price on Friday after making two announcements Thursday. Thursday morning, the company reported interim data for…

    Published on 5/3/2013
  • FINANCIAL NEWS: AltheRx raises $15M, names new CEO

    AltheRx Pharmaceuticals (Exton, Pa.) raised $15 million in a series A round led by existing investor Becker Ventures. Becker's Jim Bennethum also took over as CEO and became a director, replacing Shawn O'Brien, who …

    Published on 5/2/2013

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993

Log In


Forgot password  |  Forgot Login


If you are a subscriber, but have forgotten or never received a password, please click above to receive a new one.

The Daily Extra

Concise and authoritative news for biotech and pharma, written each business day by BioCentury’s senior editors and analysts.


Find out how to get your biopharma daily news update.